Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine

OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two decades for chronic migraine prevention. The recently approved monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) pathway open a new age for chronic migraine control. However, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Scuteri, Damiana, Tonin, Paolo, Nicotera, Pierluigi, Vulnera, Marilù, Altieri, Giuseppina Cristina, Tarsitano, Assunta, Bagetta, Giacinto, Corasaniti, Maria Tiziana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413678/
https://www.ncbi.nlm.nih.gov/pubmed/36006191
http://dx.doi.org/10.3390/toxins14080529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413678/
https://www.ncbi.nlm.nih.gov/pubmed/36006191
http://dx.doi.org/10.3390/toxins14080529

Ejemplares similares